{
    "organizations": [],
    "uuid": "3e05a13a3da907f83b96bbd600c6945be0c98858",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-announces-posi/brief-mabvax-therapeutics-announces-positive-interim-data-from-trial-of-mvt-5873-idUSASB0C55J",
    "ord_in_thread": 0,
    "title": "BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 26 PM / Updated 23 minutes ago BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873 Reuters Staff 1 Min Read \nFeb 12 (Reuters) - MabVax Therapeutics Holdings Inc : \n* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER \n* MABVAX THERAPEUTICS HOLDINGS - ‍MVT-5873 AT A DOSE OF 0.125 MG/KG WHEN ADDED TO FIRST-LINE CHEMOTHERAPY WAS GENERALLY WELL TOLERATED BY ALL SUBJECTS​ \n* MABVAX THERAPEUTICS HOLDINGS INC - ‍COMPANY PLANS TO ENROLL ADDITIONAL PATIENTS AT THIS DOSE TO FURTHER EXPLORE SAFETY AND POTENTIAL RESPONSE​ \n* MABVAX THERAPEUTICS HOLDINGS INC - ‍AT DOSE TESTED, ALL SIX PATIENTS IN COHORT HAD MEANINGFUL REDUCTIONS IN TUMOR VOLUME BY RECIST​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-12T14:25:00.000+02:00",
    "crawled": "2018-02-12T14:54:14.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "positive",
        "interim",
        "data",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "mabvax",
        "therapeutic",
        "announces",
        "positive",
        "interim",
        "data",
        "expanded",
        "cohort",
        "phase",
        "trial",
        "evaluating",
        "combination",
        "chemotherapy",
        "pancreatic",
        "cancer",
        "mabvax",
        "therapeutic",
        "holding",
        "dose",
        "added",
        "chemotherapy",
        "generally",
        "well",
        "tolerated",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "plan",
        "enroll",
        "additional",
        "patient",
        "dose",
        "explore",
        "safety",
        "potential",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "dose",
        "tested",
        "six",
        "patient",
        "cohort",
        "meaningful",
        "reduction",
        "tumor",
        "volume",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}